Assessment of cardiovascular comorbidity

European Respiratory Monograph

Volumn 59, Issue , 2013, Pages 28-49

  Maclay, John D ^a   MacNee, William ^b  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cardiovascular disease; COPD; Coronary artery disease; Vascular function

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CHOLESTEROL; CLOPIDOGREL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE PROPIONATE PLUS SALMETEROL; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; REACTIVE OXYGEN METABOLITE; TIOTROPIUM BROMIDE; TROPONIN T;

ACUTE CORONARY SYNDROME; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHEMICAL ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; EMPHYSEMA; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; META ANALYSIS (TOPIC); OXIDATIVE STRESS; PHYSIOLOGICAL STRESS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN EXPRESSION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RISK FACTOR; RISK REDUCTION; SMOKING; URINARY TRACT INFECTION;

EID: 84874913139     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10011312     Document Type: Article

References (186)

1. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795-800.
2. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-2646.
3. Friedman GD, Klatsky AL, Siegelaub AB. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med 1976; 294: 1071-1075.
4. Ebi-Kryston KL, Hawthorne VM, Rose G, et al. Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States. Int J Epidemiol 1989; 18: 84-88.
5. Ebi-Kryston K. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol 1988; 41: 251-260.
6. Gulsvik A, Hansteen V, Sivertssen E. Cardiac arrhythmias in patients with serious pulmonary diseases. Scand J Respir Dis 1978; 59: 154-159.
7. Hole D, Watt G, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-715.
8. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
9. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
10. Marcus EB, Curb JD, MacLean CJ, et al. Pulmonary function as a predictor of coronary heart disease. Am J Epidemiol 1989; 129: 97-104.
11. Schunemann H, Dorn J, Grant B, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656-664.
12. Sin DD, Wu L, Man SFP. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
13. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
14. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100: 115-122.
15. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
16. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-2107.
17. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
18. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
19. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
20. Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research 2010; 11: 122.
21. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-355.
22. Johnston A, Mannino D, Hagan G, et al. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63: 599-605.
23. Curkendall S, Lanes S, de Luise C, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006; 21: 803-813.
24. Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313-1317.
25. Knuiman MW, James AL, Divitini ML, et al. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann Epidemiol 1999; 9: 297-306.
26. Sin DD, Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
27. Engström G, Hedblad B, Janzon L, et al. Respiratory decline in smokers and ex-smokers-an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk 2000; 7: 267-272.
28. Tockman M, Pearson J, Fleg J, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 1995; 151: 390-398.
29. Zureik M, Benetos A, Neukirch C, et al. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med 2001; 164: 2181-2185.
30. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179: 35-40.
31. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 1208-1214.
32. Hadi HAR, Zubaid M, Al Mahmeed W, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol 2010; 33: 228-235.
33. Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol 2010; 106: 305-309.
34. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009; 11: 292-298.
35. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol 2007; 99: 636-641.
36. Behar S, Panosh A, Reicher-Reiss H, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am J Med 1992; 93: 637-641.
37. Bursi F, Vassallo R, Weston SA, et al. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010; 160: 95-101.
38. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010; 137: 333-340.
39. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
40. Calverley P, Anderson J, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
41. McGarvey L, John M, Anderson J, et al. Ascertainment of cause-specific mortality in COPD - operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
42. McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respir Med 2012; 106: 515-521.
43. Vilkman S, Keistinen T, Tuuponen T, et al. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997; 64: 281-284.
44. Engström G, Wollmer P, Hedblad B, et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmö, Sweden. Circulation 2001; 103: 3086-3091.
45. Garcia-Aymerich J, Farrero E, Félez MA, et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100-105.
46. Celli B, Cote C, Marin J, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
47. Stavem K, Aaser E, Sandvik L, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: 618-625.
48. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart 2012; 98: 1055-1062.
49. Sidney S, Sorel M, Quesenberry C, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
50. Patel AR, Donaldson GC, Mackay AJ, et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012; 141: 851-857.
51. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097.
52. Harvey MG, Hancox RJ. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas 2004; 16: 212-215.
53. Brekke PH, Omland T, Holmedal SH, et al. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008; 31: 563-570.
54. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66: 764-768.
55. Hoiseth AD, Neukamm A, Karlsson BD, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011; 66: 775-781.
56. McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39: 1097-1103.
57. de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J, et al. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings. BMC Cardiovasc Disord 2010; 10: 8.
58. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
59. Rutten FH, Cramer MJM, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894.
60. Mascarenhas J, Lourenco P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008; 155: 521-525.
61. Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010; 12: 1339-1244.
62. De Blois J, Simard S, Atar D, et al. COPD predicts mortality in heart failure: the Norwegian Heart Failure Registry. J Card Fail 2010; 16: 225-229.
63. Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail 2012; 14: 395-403.
64. Rusinaru D, Saaidi I, Godard S, et al. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101: 353-358.
65. Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010; 12: 685-691.
66. Engström G, Melander O, Hedblad B. Population-based study of lung function and incidence of heart failure hospitalisations. Thorax 2010; 65: 633-638.
67. Agarwal SK, Heiss G, Barr RG, et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 2012; 14: 414-422.
68. Kee K, Naughton MT. Heart failure and the lung. Circ J 2010; 74: 2507-2516.
69. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012; 67: 606-612.
70. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005; 2: 35-41.
71. Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21: 1012-1016.
72. Lahousse L, van den Bouwhuijsen Q, Loth DW, et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med 2012; [Epub ahead of print DOI: 10.1164/rccm.201206-1046OC].
73. Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA lung study. Eur Respir J 2012; 39: 846-854.
74. Basili S, Ferroni P, Vieri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis 1999; 147: 249-252.
75. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133: 19-25.
76. Incalzi RA, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794-2800.
77. Holguin F, Folch E, Redd S, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011.
78. Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
79. Bolton CE, Evans M, Ionescu AA, et al. Insulin resistance and inflammation - a further systemic complication of COPD. COPD 2007; 4: 121-126.
80. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. CMAJ 2006; 174: 801-809.
81. ten Hacken NH. Physical inactivity and obesity: relation to asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc 2009; 6: 663-667.
82. Laveneziana P, Palange P, ERS Research Seminar Faculty. Physical activity, nutritional status and systemic inflammation in COPD. Eur Respir J 2012; 40: 522-529.
83. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282.
84. Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis. JAC 2009; 54: 2129-2138.
85. van der Wal AC, Becker AE. Atherosclerotic plaque rupture - pathologic basis of plaque stability and instability. Cardiovasc Res 1999; 41: 334-344.
86. Pasterkamp G, Schoneveld AH, Van Der Wal AC, et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol 1999; 19: 54-58.
87. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
88. Ridker P, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
89. Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008; 359: 2195-2207.
90. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
91. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
92. Man SFP, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853.
93. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
94. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-2618.
95. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
96. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. J Am Coll Cardiol 2010; 55: 1318-1327.
97. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
98. Barr RG, Mesia-Vela S, Austin JHM, et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) study. Am J Respir Crit Care Med 2007; 176: 1200-1207.
99. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable COPD. Am J Respir Crit Care Med 2008; 178: 1211-1218.
100. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 513-520.
101. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
102. Solomon SD, Lin J, Solomon CG, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 2007; 116: 2687-2693.
103. Casanova C, De Torres JP, Navarro J, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 1004-1010.
104. van Dijk EJ, Vermeer SE, de Groot JC, et al. Arterial oxygen saturation, COPD, and cerebral small vessel disease. J Neurol Neurosurg Psychiatr 2004; 75: 733-736.
105. Dodd JW, Chung AW, Van Den Broek MD, et al. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med 2012; 186: 240-245.
106. Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol 2008; 105: 1643-1651.
107. Black PN, Ching PST, Beaumont B, et al. Changes in elastic fibres in the small airways and alveoli in COPD. Eur Respir J 2008; 31: 998-1004.
108. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax 2006; 61: 568-571.
109. Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003; 4: 11.
110. Yasmin, McEniery CM., Wallace S., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372.
111. Yasmin, McEniery CM, O'Shaughnessy KM, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006; 26: 1799-1805.
112. Chung AWY, Yang HHC, Kim JM, et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009; 120: 792-801.
113. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
114. Lee YW, Kuhn H, Hennig B, et al. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001; 33: 83-94.
115. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med 1998; 132: 9-15.
116. Aoki M, Nata T, Morishita R, et al. Endothelial apoptosis induced by oxidative stress through activation of NF- kB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension 2001; 38: 48-55.
117. Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003; 24: 2180-2185.
118. Mills NL, Törnqvist H, Robinson SD, et al. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation 2005; 112: 3930-3936.
119. Lattimore J-DL, Wilcox I, Nakhla S, et al. Repetitive hypoxia increases lipid loadingin human macrophages-a potentially atherogenic effect. Atherosclerosis 2005; 179: 255-259.
120. Ichikawa H, Flores S, Kvietys PR, et al. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ Res 1997; 81: 922-931.
121. Hartmann G, Tschöp M, Fischer R, et al. High altitudeincreases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 2000; 12: 246-252.
122. Thomson AJ, Drummond G, Waring WS, et al. Effects of short-term isocapnic hyperoxia and hypoxia on cardiovascular function. J Appl Physiol 2006; 101: 809-816.
123. Skwarski KM, Morrison D, Barratt A, et al. Effects of hypoxia on renal hormonal balance in normal subjects and in patients with COPD. Respir Med 1998; 92: 1331-1336.
124. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002; 77: 45-54.
125. Heindl S, Lehnert M, Criée CP, et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001; 164: 597-601.
126. Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994; 90: 878-883.
127. Volterrani M, Scalvini S, Mazzuero G, et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest 1994; 106: 1432-1437.
128. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.
129. Lee H, Lee J, Lee K, et al. Relation between COPD severity and global cardiovascular risk in U.S. adults. Chest 2012; 142: 1118-1125.
130. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
131. Baillard C, Boussarsar M, Fosse JP, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2003; 29: 584-589.
132. Søyseth V, Brekke P, Smith P, et al. Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 279-283.
133. Kragelund C, Grønning B, Køber L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666-675.
134. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012; 39: 51-58.
135. Sabit R, Bolton CE, Fraser AG, et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med 2010; 104: 1171-1178.
136. Barr R, Bluemke D, Ahmed F. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217-227.
137. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42: 1226-1233.
138. Vizza C, Lynch J, Ochoa L, et al. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998; 113: 576-583.
139. Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment of arterial stiffness in clinical practice. QJM 2002; 95: 67-74.
140. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664-670.
141. Tillin T, Chambers J, Malik I, et al. Measurement of pulse wave velocity: site matters. J Hypertens 2007; 25: 383-389.
142. London GM, Blacher J, Pannier B, et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438.
143. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
144. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-1265.
145. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008; 63: 306-311.
146. Dransfield MT, Huang F, Nath H, et al. CT emphysema predicts thoracic aortic calcification in smokers with and without COPD. COPD 2010; 7: 404-410.
147. Bolton CE, McEniery CM, Raj V, et al. Aortic calcification, arterial stiffness and bone mineral density in patients with COPD. Artery Res 2011; 5: 30-36.
148. McAllister DA, Macnee W, Duprez D, et al. Pulmonary function is associated with distal aortic calcium, not proximal aortic distensibility. MESA lung study. COPD 2011; 8: 71-78.
149. 18F-FDG PET pilot study. J Nucl Med 2010; 51: 1357-1360.
150. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001; 52: 631-646.
151. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
152. Newby D, Wright R, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking - a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 99: 1411-1415.
153. Chowienczyk PJ, Watts GF, Cockcroft JR, et al. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992; 340: 1430-1432.
154. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-2516.
155. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14: Suppl. 2, S1-S113.
156. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381.
157. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
158. Mancini G, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
159. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
160. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smoker. Chest 2007; 132: 1764-1771.
161. van Gestel YRBM, Hoeks SE, Sin DD, et al. Impact of cardioselective b-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178: 695-700.
162. Frost FJ, Peterssen H, Tollestrup L, et al. Influenza and COPD mortality prediction as pleiotropic, dosedependent effects of statins. Chest 2007; 131: 1006-1012.
163. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbations and the requirements for incubation in patients with COPD: evidence from a prospective cohort study.: Int J Clin Pract 2008; 62: 1373-1378.
164. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
165. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988; 260: 2088-2093.
166. Freemantle N, Urdahl H, Eastaugh J, et al. What is the place of b-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation. Prog Cardiovasc Dis 2002; 44: 243-250.
167. Egred M, Shaw S, Mohammad B, et al. Under-use of b-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98: 493-497.
168. Olenchock BA, Fonarow GG, Pan W, et al. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009; 103: 295-300.
169. Dransfield M, Rowe S, Johnson J, et al. b-blocker use and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax 2008; 63: 301-305.
170. Goldberger JJ, Bonow RO, Cuffe M, et al. b-blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J 2010; 160: 435-442.
171. Nishiyama K, Morimoto T, Furukawa Y, et al. Chronic obstructive pulmonary disease-an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. Int J Cardiol 2010; 143: 178-183.
172. Selvaraj CL, Gurm HS, Gupta R, et al. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 2005; 96: 756-759.
173. Campo G, Saia F, Guastaroba P, et al. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch Intern Med 2011; 171: 1948-1949.
174. Rutten FH. b-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease. Future Cardiol 2011; 7: 43-53.
175. Maedera MT, Stöcklib M, Zellwegera MJ. Adenosine-induced severe acute respiratory distress in chronic obstructive pulmonary disease: a myth? Swiss Med Wkly 2007; 137: 212.
176. Wu J, Sin DD. Improved patient outcome with smoking cessation: when is it too late? Int J Chron Obstruct Pulmon Dis 2011; 6: 259-267.
177. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.
178. Stoller JK, Panos RJ, Krachman S, et al. Oxygen therapy for patients with COPD: current evidence and the longterm oxygen treatment trial. Chest 2010; 138: 179-187.
179. Puhan M, Scharplatz M, Troosters T, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; 1: CD005305.
180. Moore RL. Cellular adaptations of the heart muscle to exercise training. Ann Med 1998; 30: Suppl. 1, 46-53.
181. Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med 2011; 11: 20.
182. Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010; 65: 719-725.
183. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
184. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-955.
185. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J 2010; 35: 1003-1021.
186. Dransfield MT, Cockroft JR, Townsend RR, et al. Effect of fluticasone proprionate/salmeterol on arterial stiffness in patients with COPD. Respir Med 2011; 105: 1323-1330.